An open‐label, single‐arm, dose‐escalating concentration–QT study to investigate the cardiac effects and safety of paroxetine in healthy adults
Paroxetine does not prolong QTc interval in healthy individuals to any clinically meaningful extent at therapeutically relevant doses. This study supports the favourable cardiac safety profile of paroxetine.
Authors
- Sanman Ghorpade
- O Della Pasqua
- Sven C. van Dijkman (ORCID: https://orcid.org/0000-0002-2799-7643)
- Mathieu Felices
- Bhaskar Pandurangavittal
- Caroline Easterbrook
- Marcin Zabielski
Institutions
- Icon (India) (IN)
- GlaxoSmithKline (India) (IN)
- GlaxoSmithKline (Poland) (PL)
- e-Therapeutics (United Kingdom) (GB)
- Imperial Consultants (GB)
- University College London (GB)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2026-01-14
- DOI
- https://doi.org/10.1002/bcp.70398
- Primary Topic
- Cardiac electrophysiology and arrhythmias
- Type
- article
- Field-Weighted Citation Impact
- 0.00